ACLX Arcellx Inc
Price (delayed)
$60.25
Market cap
$3.31B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2
Enterprise value
$3.26B
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which
Highlights
Arcellx's debt has decreased by 45% YoY and by 17% from the previous quarter
Arcellx's quick ratio has decreased by 21% YoY but it has increased by 12% from the previous quarter
The EPS has dropped by 182% since the previous quarter and by 36% year-on-year
Arcellx's net income has plunged by 166% from the previous quarter and by 52% YoY
Key stats
What are the main financial stats of ACLX
Market
Valuations
Earnings
Shares outstanding
54.94M
Market cap
$3.31B
Enterprise value
$3.26B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.16
Price to sales (P/S)
29.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.19
Revenue
$107.94M
Gross profit
$107.94M
Operating income
-$137.57M
Net income
-$107.35M
EBIT
-$137.57M
EBITDA
-$128.28M
Free cash flow
-$96.9M
Per share
Balance sheet
Liquidity
EPS
-$2
EPS diluted
-$2
Free cash flow per share
-$1.81
Book value per share
$8.41
Revenue per share
$2.02
TBVPS
$13.28
Total assets
$711.33M
Total liabilities
$256.54M
Debt
$54.08M
Equity
$454.79M
Working capital
$473.91M
Debt to equity
0.12
Current ratio
4.78
Quick ratio
4.69
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
-118.8%
Gross margin
100%
Net margin
-99.5%
Operating margin
-127.5%
Return on assets
-14.4%
Return on equity
-22.3%
Return on invested capital
-24%
Return on capital employed
-23.5%
Return on sales
-127.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACLX stock price
How has the Arcellx stock price performed over time
Intraday
-8.16%
1 week
-16.5%
1 month
-7.05%
1 year
-10.05%
YTD
-21.44%
QTD
-8.16%
Financial performance
How have Arcellx's revenue and profit performed over time
Revenue
$107.94M
Gross profit
$107.94M
Operating income
-$137.57M
Net income
-$107.35M
Gross margin
100%
Net margin
-99.5%
Arcellx's operating margin has plunged by 186% from the previous quarter and by 56% YoY
Arcellx's net income has plunged by 166% from the previous quarter and by 52% YoY
The company's operating income has shrunk by 98% QoQ and by 53% YoY
Arcellx's net margin has plunged by 55% YoY
Growth
What is Arcellx's growth rate over time
Valuation
What is Arcellx stock price valuation
P/E
N/A
P/B
7.16
P/S
29.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.19
The EPS has dropped by 182% since the previous quarter and by 36% year-on-year
The equity has declined by 6% year-on-year and by 6% since the previous quarter
ACLX's price to book (P/B) is 2.5% lower than its last 4 quarters average of 8.0
The company's revenue fell by 31% QoQ and by 2.2% YoY
The price to sales (P/S) is 13% higher than the last 4 quarters average of 28.8
Efficiency
How efficient is Arcellx business performance
Arcellx's return on assets has shrunk by 177% QoQ and by 37% YoY
The company's return on equity has shrunk by 169% QoQ and by 6% YoY
ACLX's return on invested capital has dropped by 112% since the previous quarter but it is up by 10% year-on-year
The return on sales has dropped by 56% year-on-year
Dividends
What is ACLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACLX.
Financial health
How did Arcellx financials performed over time
ACLX's total assets is 177% higher than its total liabilities
Arcellx's total liabilities has decreased by 24% YoY and by 9% from the previous quarter
Arcellx's quick ratio has decreased by 21% YoY but it has increased by 12% from the previous quarter
Arcellx's debt is 88% less than its equity
Arcellx's debt has decreased by 45% YoY and by 17% from the previous quarter
ACLX's debt to equity is down by 40% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.